1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zhuhai Rundu Pharmaceutical Co. Ltd. Class A

Zhuhai Rundu Pharmaceutical Co. Ltd. Class A

SSZSE:002923
9.15
CNY
-0.05
(-0.54%)
-0.02EPS
3.17BMarket Cap
Zhuhai Rundu Pharmaceutical Co. Ltd. Class A
SZSE:002923
(Shenzhen Stock Exchange)

Recent

price

9.15

P/E

ratio

- -

div

yld

2.08%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.27
1.46
1.76
2.12
2.36
2.66
3.18
3.17
4.02
3.75
3.53
4.06
3.86
3.56
3.52
3.93
Revenue per Share
0.13
0.23
0.24
0.24
0.29
0.36
0.37
0.32
0.35
0.41
0.41
0.46
0.2
0.12
-0.19
-0.02
Basic EPS, GAAP
- -
- -
- -
0.16
-0.06
0.12
0.22
0.13
-0.26
-0.02
-0.51
-0.35
-0.01
0.39
0.26
- -
Free Cash Flow per Basic Share
- -
0.1
0.08
0.12
0.15
0.02
0.02
0.22
0.22
0.23
0.24
0.27
0.31
0.25
0.19
0.19
Dividend per Share
0.67
0.81
0.96
1.11
1.26
1.62
1.49
2.66
2.79
3.07
3.29
3.57
3.52
3.44
3.1
3.22
Book Value per Share
0.56
0.7
0.86
1.01
1.17
1.52
1.42
2.59
2.64
2.87
3.09
3.37
3.32
3.25
2.91
3.04
Tangible Book Value per Share
245
247
246
247
245
245
245
330
338
334
337
338
334
332
334
329
Basic Weighted Avg Shares
311
362
434
524
578
652
779
1,044
1,360
1,253
1,190
1,372
1,292
1,182
1,176
1,294
Sales/Revenue/Turnover
13.1
17.11
15.16
13.31
14.11
13.78
14.52
10.47
9.53
12.73
13.43
15.92
10.98
6.16
1.87
4.79
Operating Margin (%)
- -
- -
- -
14
16
20
31
31
38
50
64
72
113
137
143
- -
Depreciation Expense
32
57
59
60
71
87
91
107
119
136
140
155
67
40
-63
-6
Net Income, GAAP
24.47
15.13
15
14.33
14.08
13.34
10.96
10.75
10.23
8.71
7.89
14.07
22.25
6.44
- -
- -
Effective Tax Rate (%)
10.35
15.64
13.67
11.37
12.31
13.42
11.63
10.24
8.74
10.85
11.75
11.33
5.18
3.37
-5.4
-0.47
Profit Margin (%)
87
117
128
139
139
216
295
624
487
413
385
357
420
362
321
378
Working Capital
- -
- -
- -
- -
50
80
47
29
11
5
251
378
441
367
312
264
LT Debt
165
199
236
273
311
398
489
871
940
1,038
1,112
1,196
1,179
1,152
1,038
1,079
Total Equity
- -
23.91
20.29
18.46
18.37
15.87
16.72
14.06
12.62
13.48
11.27
10.09
3.9
2.42
- -
- -
Return on Invested Capital (%)
- -
28.36
25.13
21.61
20.61
19.85
17.55
14.69
12.78
13.19
11.25
10.54
4.65
3.21
- -
- -
Return on Capital (%)
- -
31.03
27.25
23.36
24.37
24.68
20.44
15.71
13.13
13.73
13
13.47
5.63
3.42
-5.8
-0.55
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
221
185
192
LT Borrowings
310
289
263
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
335
335
335
Market Capitalization
4,069
5,248
3,168

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
856
847
923
Cash, Cash Equivalents & STI
256
246
308
Accounts Receivable, Net
137
156
195
Inventories
395
374
357
Total Current Liabilities
535
498
545
Payables & Accruals
- -
- -
- -
ST Debt
221
185
192
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.86%
0.22%
-9.87%
Free Cash Flow
-532.98%
-940.54%
-33.47%
Net Income, GAAP
-27.24%
-68.48%
-259.14%
Sales/Revenue/Turnover
8.41%
-0.91%
-0.51%
Total Cash Common Dividend
123%
-2.13%
-24.33%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
306
291
280
305
1,182
2025
255
293
- -
292
1,176
2026
349
360
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.03
- -
0.01
0.12
2025
0.01
-0.11
- -
-0.03
-0.19
2026
0.05
0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.21
0.01
0.01
0.25
2025
0.02
0.16
- -
0.01
0.19
2026
0.01
0.01
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ) engages in the research, development, production, and sale of chemical pharmaceutical preparations, active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and pellets. The company offers core products including isosorbide mononitrate sustained-release capsules, voriconazole dry suspensions, rabeprazole sodium enteric capsules and tablets, ibuprofen sustained-release capsules, irbesartan capsules and tablets, valsartan, sacubitril valsartan sodium, candesartan cilexetil, nicergoline, and valacyclovir hydrochloride tablets; these span therapeutic areas such as cardiovascular and cerebrovascular systems, anti-infectives, peptic ulcer, hypertension, surgical anesthesia, antipyretic analgesics, digestive disorders, and diabetes. Founded in 1999 and headquartered in Jinwan District, Zhuhai City, Guangdong Province, China, the company operates primarily in China with international regulatory approvals including WHO, EDQM CEP, Japan PMDA, and US FDA inspections, and employs over 2,000 staff across its GMP-certified facilities. Rundu maintains a vertically integrated model from APIs to finished dosage forms like tablets, capsules, and micro-pills, positioning it as a national high-tech enterprise, Guangdong technology center, and green factory with 52 preparation registrations, 27 APIs, 10 new drug certificates, and 183 patents. In recent developments, Valacyclovir Hydrochloride Tablets (0.5g) passed the National Medical Products Administration's quality and efficacy consistency evaluation for generic drugs in 2025, enhancing its generic portfolio; the company also sustained recognition as one of Guangdong's top 100 chemical enterprises in 2023 and a top ten pharmaceutical innovation firm in Zhuhai in 2024.